Literature DB >> 8649580

Mitochondrial DNA in migraine with aura.

T Klopstock1, A May, P Seibel, E Papagiannuli, H C Diener, H Reichmann.   

Abstract

Migraine and the MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) syndrome have some clinical features in common. First, cerebral infarctions, most often in the posterior cerebral regions, which are a main symptom of MELAS, may complicate migraine. Second, migrainous headache with vomiting is also a characteristic feature of the MELAS syndrome. Less frequently, hemicranial headache is present in another mitochondrial disease, myoclonic epilepsy with ragged-red fibers (MERRF). Moreover, there is a mild bias toward maternal transmission in migraine. Apart from clinical resemblance, there is some experimental evidence for mitochondrial dysfunction in migraine. There may be depression of respiratory chain enzyme activity in muscle and platelets, and magnetic resonance spectroscopy has revealed a defective energy metabolism in brain and muscle of migraine patients. There has not been a systematic study of mitochondrial DNA in migraine, however. We therefore analyzed the mitochondrial DNA in lymphocytes of 23 migraine patients with aura. Southern blot and polymerase chain reaction analysis of mitochondrial DNA failed to detect any large-scale deletions or point mutations at base pair 3243 (MELAS) and base pair 8344 (MERRF). Our data show that deletions of mitochondrial DNA and the most frequent point mutations of MELAS and MERRF syndromes are not common in migraine with aura. In particular, these data do not support the hypothesis that some cases of migraine may be monosymptomatic forms of a MELAS syndrome. We cannot exclude, however, that migraine may be associated with different point mutations of mitochondrial DNA or with mutations of autosomally coded respiratory chain subunit genes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8649580     DOI: 10.1212/wnl.46.6.1735

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

Review 1.  Clinical mitochondrial genetics.

Authors:  P F Chinnery; N Howell; R M Andrews; D M Turnbull
Journal:  J Med Genet       Date:  1999-06       Impact factor: 6.318

Review 2.  Antithrombotic therapy for stroke in young adults.

Authors:  Jeremy R Payne; Bruce Coull
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

Review 3.  Migraine and epilepsy in the pediatric population.

Authors:  Christopher B Oakley; Eric H Kossoff
Journal:  Curr Pain Headache Rep       Date:  2014-03

Review 4.  The Relationship Between Headaches with Epileptic and Non-epileptic Seizures: a Narrative Review.

Authors:  William S Kingston; Todd J Schwedt
Journal:  Curr Pain Headache Rep       Date:  2017-03

Review 5.  A possible role for mitochondrial dysfunction in migraine.

Authors:  S Stuart; L R Griffiths
Journal:  Mol Genet Genomics       Date:  2012-10-07       Impact factor: 3.291

Review 6.  Migralepsy: a borderland of wavy lines.

Authors:  Amy Z Crepeau
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

Review 7.  Mitochondrial vasculopathy.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  World J Cardiol       Date:  2016-05-26

Review 8.  Pathophysiology of Migraine: A Disorder of Sensory Processing.

Authors:  Peter J Goadsby; Philip R Holland; Margarida Martins-Oliveira; Jan Hoffmann; Christoph Schankin; Simon Akerman
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

9.  Screening of the A11084G Polymorphism and Scanning of a Mitochondrial Genome SNP in Korean Migraineurs.

Authors:  Lami Kang; Soon-Tae Lee; Wooseok Im; Seung Chan Kim; Kim Sung Hun; Byung-Kun Kim; Manho Kim
Journal:  J Clin Neurol       Date:  2007-09-20       Impact factor: 3.077

Review 10.  The metabolic face of migraine - from pathophysiology to treatment.

Authors:  Elena C Gross; Marco Lisicki; Dirk Fischer; Peter S Sándor; Jean Schoenen
Journal:  Nat Rev Neurol       Date:  2019-10-04       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.